Search Results - "Yarimizu, Junko"

Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine by Nagakura, Akira, Shitaka, Yoshitsugu, Yarimizu, Junko, Matsuoka, Nobuya

“…Alzheimer's disease is characterized by a progressive decline in cognitive function and involves β-amyloid (Aβ) in its pathogenesis. To characterize cognitive…”
Get full text

Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats by Yamazaki, Mayako, Okabe, Mayuko, Yamamoto, Noriyuki, Yarimizu, Junko, Harada, Katsuya

“…Despite the human 5-HT5A receptor being cloned in 1994, the biological function of this receptor has not been extensively characterized due to a lack of…”
Get full text

A Comparative Study on the Hydroperoxide and Thiol Specificity of the Glutathione Peroxidase Family and Selenoprotein P by Takebe, Gen, Yarimizu, Junko, Saito, Yoshiro, Hayashi, Takaaki, Nakamura, Hajime, Yodoi, Junji, Nagasawa, Shigeharu, Takahashi, Kazuhiko

“…Glutathione peroxidase catalyzes the reduction of hydrogen peroxide and organic hydroperoxide by glutathione and functions in the protection of cells against…”
Get full text

Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition by Mihara, Takuma, Mihara, Kayoko, Yarimizu, Junko, Mitani, Yasuyuki, Matsuda, Ritsuko, Yamamoto, Hiroko, Aoki, Satoshi, Akahane, Atsushi, Iwashita, Akinori, Matsuoka, Nobuya

“…Central adenosine A(2A) receptor is a promising target for drugs to treat Parkinson's disease (PD), and the central blockade of adenosine A(1) receptor…”
Get more information

Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice by Mitani, Yasuyuki, Yarimizu, Junko, Saita, Kyoko, Uchino, Hiroshi, Akashiba, Hiroki, Shitaka, Yoshitsugu, Ni, Keni, Matsuoka, Nobuya

“…γ-Secretase inhibitors (GSIs) reduce amyloid-β (Aβ) peptides but inevitably increase the β-C-terminal fragment (β-CTF) of amyloid precursor protein (APP),…”
Get full text

5-HT5A Receptor Antagonist ASP5736 Ameliorates Several Abnormal Behaviors in an Fmr1- Targeted Transgenic Male Rat Model of Fragile X Syndrome by Yamazaki, Mayako, Arai, Takatomo, Yarimizu, Junko, Matsumoto, Mitsuyuki

“…Abstract Background Fragile X syndrome (FXS) is a genetic condition that causes a range of developmental problems, including intellectual disability,…”
Get full text

5-H[T.sub.5A] Receptor Antagonist ASP5736 Ameliorates Several Abnormal Behaviors in an Fmr1-Targeted Transgenic Male Rat Model of Fragile X Syndrome by Yamazaki, Mayako, Arai, Takatomo, Yarimizu, Junko, Matsumoto, Mitsuyuki

“…Background: Fragile X syndrome (FXS) is a genetic condition that causes a range of developmental problems, including intellectual disability, aggressive…”
Get full text

Optimization and biological evaluation of imidazopyridine derivatives as a novel scaffold for γ-secretase modulators with oral efficacy against cognitive deficits in Alzheimer’s disease model mice by Sekioka, Ryuichi, Honda, Shugo, Akashiba, Hiroki, Yarimizu, Junko, Mitani, Yasuyuki, Yamasaki, Shingo

“…[Display omitted] Gamma-secretase modulators (GSMs) selectively lower amyloid-β42 (Aβ42) and are therefore potential disease-modifying drugs for Alzheimer’s…”
Get full text

Efficiency of selenocysteine incorporation in human thioredoxin reductase by Yarimizu, J, Nakamura, H, Yodoi, J, Takahashi, K

“…Thioredoxin reductase (TR) is a flavoenzyme, containing one selenocysteine (Sec) residue at the penultimate carboxyl-terminus, that catalyzes the…”
Get more information

Neurochemical and neuropharmacological characterization of ASP2905, a novel potent selective inhibitor of the potassium channel KCNH3 by Takahashi, Shinji, Inamura, Kohei, Yarimizu, Junko, Yamazaki, Mayako, Murai, Nobuhito, Ni, Keni

“…KCNH3 (BEC1) is a member of the ether-à-go-go (KCNH) family of voltage-gated K+ channels. The aim of this study was to determine the pharmacological profiles…”
Get full text

ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia by Yamazaki, Mayako, Harada, Katsuya, Yamamoto, Noriyuki, Yarimizu, Junko, Okabe, Mayuko, Shimada, Takeshi, Ni, Keni, Matsuoka, Nobuya

“…Abstract We recently identified ASP5736, ( N -(diaminomethylene)-1-(3,5-difluoropyridin-4-yl)-4-fluoroisoquinoline-7-carboxamide (2 E )-but-2-enedioate), a…”
Get full text

A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease by Harada, Katsuya, Nakato, Kazuhiro, Yarimizu, Junko, Yamazaki, Mayako, Morita, Masahiko, Takahashi, Shinji, Aota, Masaki, Saita, Kyoko, Doihara, Hitoshi, Sato, Yuichiro, Yamaji, Takayuki, Ni, Keni, Matsuoka, Nobuya

“…Hypofunction of brain N-methyl-d-aspartate (NMDA) receptors has been implicated in psychiatric disorders such as schizophrenia and Alzheimer's disease…”
Get full text

Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble A beta 42 without affecting other A beta pools by Mitani, Yasuyuki, Yarimizu, Junko, Akashiba, Hiroki, Shitaka, Yoshitsugu, Ni, Keni, Matsuoka, Nobuya

“…Given that amyloid- beta 42 (A beta 42) is believed to be a culprit in Alzheimer's disease (AD), reducing A beta 42 production should be a potential…”
Get full text

Functional mechanism of ASP5736, a selective serotonin 5-HT 5A receptor antagonist with potential utility for the treatment of cognitive dysfunction in schizophrenia by Yamazaki, Mayako, Yamamoto, Noriyuki, Yarimizu, Junko, Okabe, Mayuko, Moriyama, Ai, Furutani, Masako, Marcus, Monica M, Svensson, Torgny H, Harada, Katsuya

“…The 5-HT receptor is arguably the least understood 5-HT receptor. Despite widespread expression in human and rodent brains it lacks specific ligands. Our…”
Get full text

Functional mechanism of ASP5736, a selective serotonin 5-HT5A receptor antagonist with potential utility for the treatment of cognitive dysfunction in schizophrenia by Yamazaki, Mayako, Yamamoto, Noriyuki, Yarimizu, Junko, Okabe, Mayuko, Moriyama, Ai, Furutani, Masako, Marcus, Monica M., Svensson, Torgny H., Harada, Katsuya

“…The 5-HT5A receptor is arguably the least understood 5-HT receptor. Despite widespread expression in human and rodent brains it lacks specific ligands. Our…”
Get full text

Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates by Mitani, Yasuyuki, Akashiba, Hiroki, Saita, Kyoko, Yarimizu, Junko, Uchino, Hiroshi, Okabe, Mayuko, Asai, Makoto, Yamasaki, Shingo, Nozawa, Takashi, Ishikawa, Noritoshi, Shitaka, Yoshitsugu, Ni, Keni, Matsuoka, Nobuya

“…γ-Secretase is the enzyme responsible for the intramembranous proteolysis of various substrates, such as amyloid precursor protein (APP) and Notch. Amyloid-β…”
Get full text

Amelioration of cognitive deficits in plaque‐bearing Alzheimer's disease model mice through selective reduction of nascent soluble Aβ42 without affecting other Aβ pools by Mitani, Yasuyuki, Yarimizu, Junko, Akashiba, Hiroki, Shitaka, Yoshitsugu, Ni, Keni, Matsuoka, Nobuya

“…Given that amyloid‐β 42 (Aβ42) is believed to be a culprit in Alzheimer's disease (AD), reducing Aβ42 production should be a potential therapeutic approach…”
Get full text

Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble A[beta]42 without affecting other A[beta] pools by Mitani, Yasuyuki, Yarimizu, Junko, Akashiba, Hiroki, Shitaka, Yoshitsugu, Ni, Keni, Matsuoka, Nobuya

“…Given that amyloid-[beta] 42 (A[beta]42) is believed to be a culprit in Alzheimer's disease (AD), reducing A[beta]42 production should be a potential…”
Get full text

Amelioration of cognitive deficits in plaque‐bearing A lzheimer's disease model mice through selective reduction of nascent soluble A42 without affecting other A pools by Mitani, Yasuyuki, Yarimizu, Junko, Akashiba, Hiroki, Shitaka, Yoshitsugu, Ni, Keni, Matsuoka, Nobuya

“…Abstract Given that amyloid‐β 42 (Aβ42) is believed to be a culprit in Alzheimer's disease ( AD ), reducing Aβ42 production should be a potential therapeutic…”
Get full text

evolutionarily conserved G protein-coupled receptor SREB2/GPR85 influences brain size, behavior, and vulnerability to schizophrenia by Matsumoto, Mitsuyuki, Straub, Richard E, Marenco, Stefano, Nicodemus, Kristin K, Matsumoto, Shun-ichiro, Fujikawa, Akihiko, Miyoshi, Sosuke, Shobo, Miwako, Takahashi, Shinji, Yarimizu, Junko, Yuri, Masatoshi, Hiramoto, Masashi, Morita, Shuji, Yokota, Hiroyuki, Sasayama, Takeshi, Terai, Kazuhiro, Yoshino, Masayasu, Miyake, Akira, Callicott, Joseph H, Egan, Michael F, Meyer-Lindenberg, Andreas, Kempf, Lucas, Honea, Robyn, Vakkalanka, Radha Krishna, Takasaki, Jun, Kamohara, Masazumi, Soga, Takatoshi, Hiyama, Hideki, Ishii, Hiroyuki, Matsuo, Ayako, Nishimura, Shintaro, Matsuoka, Nobuya, Kobori, Masato, Matsushime, Hitoshi, Katoh, Masao, Furuichi, Kiyoshi, Weinberger, Daniel R

“…The G protein-coupled receptor (GPCR) family is highly diversified and involved in many forms of information processing. SREB2 (GPR85) is the most conserved…”
Get full text